GSA Capital Partners LLP Acquires Shares of 472,564 Aldeyra Therapeutics, Inc. $ALDX

GSA Capital Partners LLP bought a new position in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 472,564 shares of the biotechnology company’s stock, valued at approximately $1,007,000. GSA Capital Partners LLP owned approximately 0.78% of Aldeyra Therapeutics at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. The Manufacturers Life Insurance Company raised its position in Aldeyra Therapeutics by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,074 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 1,972 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Aldeyra Therapeutics by 2.7% in the 2nd quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 2,018 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Aldeyra Therapeutics by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 152,787 shares of the biotechnology company’s stock valued at $791,000 after buying an additional 2,309 shares during the period. Federation des caisses Desjardins du Quebec raised its position in shares of Aldeyra Therapeutics by 25.8% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Aldeyra Therapeutics by 0.8% during the fourth quarter. Deutsche Bank AG now owns 317,335 shares of the biotechnology company’s stock valued at $1,644,000 after acquiring an additional 2,607 shares during the period. 59.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on ALDX shares. Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.50.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, CEO Todd C. Brady purchased 250,000 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $1.67 per share, with a total value of $417,500.00. Following the purchase, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at $2,874,567.66. The trade was a 16.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 11.80% of the stock is currently owned by company insiders.

Aldeyra Therapeutics Price Performance

NASDAQ ALDX opened at $1.56 on Tuesday. Aldeyra Therapeutics, Inc. has a one year low of $1.07 and a one year high of $6.17. The stock’s 50-day moving average is $1.80 and its 200-day moving average is $2.56. The firm has a market cap of $94.11 million, a P/E ratio of -4.00 and a beta of 1.22.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Equities analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.